Castle Biosciences (CSTL) will share data supporting its dermatologic portfolio of tests for skin cancer, DecisionDx-SCC, DecisionDx)-Melanoma and MyPath Melanoma, through poster presentations at the annual Maui Derm Hawaii meeting, being held Jan. 20-24, 2025, in Maui, Hawaii. The Company’s poster on DecisionDx-SCC, which was selected as a “Late Breakers” top five finalist for the best poster Akamai Award, shares new data from a study involving Castle’s largest cohort of patients with cutaneous squamous cell carcinoma, SCC, to date. This study demonstrates improved risk stratification of patients with SCC tumors located on the head or neck when the test’s results are combined with Brigham and Women’s Hospital staging.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CSTL:
- Castle Biosciences Projects Strong Revenue Growth for 2024
- Castle expects FY24 revenue to meet or exceed top end of $320M-$330M guidance
- Castle Biosciences drops as regional Medicare contractor won’t cover test
- Castle Biosciences gets NYSDOH approval for TissueCypher BE test
- Stephens lays out 21 Best Ideas for 2025